

Biotech Capital.

Biotech Capital (BTC) -ASX Announcement

14 March 2017

BIOINTELECT APPOINTS SENIOR CLINICAL SERVICES EXECUTIVE

Biotech Capital Limited (ASX:BTC) announced today that its wholly owned subsidiary Biointellect Pty Ltd has appointed Dr. Ric DeGaris as Clinical Services Director in its Melbourne office to lead the group's clinical development services for its local and international clients.

Ric has a BSc and Ph.D. in Pharmacology from Monash University. He has over 25 years experience in biomedical research, clinical operations, product development and commercialisation, working with a range of pharma, biotech and start-up companies, as well as research organisations and institutes.

He was formerly the Managing Director of Kendle Australia, responsible for the operations and growth of the Australian subsidiary. Under his leadership the local business made a strong contribution and played a key role within the Asia-Pacific region.

Biotech Capital's Chairman Dr. Richard Treagus commented; "Ric brings a wealth of clinical and commercial experience, as well as first class industry relationships. Given his proven business building capabilities and leadership skills, we are very fortunate to have him join our growing Biointellect team."

About Biotech Capital Limited

Biotech Capital is a listed entity on the ASX and is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. The company's strategy is to make active investments in life science businesses and late-stage product development opportunities that will benefit from greater access to development capital. The company has the longer-term objective of building a group of complimentary businesses that are entrepreneurial, innovative, globally focused and when operating together have the ability to generate better health outcomes and add value for its shareholders.

Under the Pooled Development Funds Act 1992, shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Gains realised on the disposal of shares will not be included in an investor's assessable income in Australia. An investor will not be entitled to any deduction or capital loss on the sale of shares. Unfranked dividends received by an Australian resident will be exempt from tax. Franked dividends will also be exempt from tax unless the shareholder elects to be taxed. An Australian corporate tax entity may credit its franking account (with franking credits attaching to a franked dividend), regardless of whether it has elected to treat the dividend as exempt or assessable income. Dividends paid to non-residents will not be subject to withholding tax. A shareholder or prospective shareholder should obtain their own tax advice rather than relying on this summary.

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Biotech Capital to be materially different from the statements in this announcement.

Biotech Capital.

For more information, please contact:

Dr. Richard Treagus, Executive Chairman
rtreagus@biotechcapital.com.au +61 417 520509